Boston Scientific launches the very first iPhone app for ICD patients.

Boston Scientific has launched the first of a series of iPhone apps aimed at giving ICD patients a higher level of control and customer service. Patients can set up a personal profile and search for others based on device type, age, gender, number of shocks, etc.

It’s a great way for patients to meet, connect and support each other and a smart way for Boston Scientific to build their brand as a new era of empowered patients emerges.

   

Of course, the above is not true (at least not yet). It is only wishful thinking on my part. I have no knowledge that Boston Scientific (or other device manufacturer) is working on such an app.

But I hope the day will come when patients will be able to use their smart phones to find and connect with others, view our device's settings, review the electrogram of an arrhythmic event, or even download our heart's data from a remote monitoring network (Boston Scientific's Latitude Patient Management System, for example).

Other useful applications could include an app that allows for patients to keep an event log, recording activities such as eating, walking, or driving and symptoms such as palpitations, dizziness and shortness of breath. This data could be sent to a networked printer, transmitted by email, or downloaded to a personal computer and later matched up by a doctor or nurse to an interrogation report.

Ultimately, I'd really like to be able to download the electrogram for an arrhythmia, display a "dashboard" with my device's programming settings, event summary, pacing percentage, battery life, etc.

Such access to information could be a compelling selling point when it comes time for an ICD to get replaced. It's all about control. And control translates into true cardiac disease management.

And whoever provides us patients the highest level of control—and service—is more likely to get our business.

Genetic testing and me.

Today I agreed to have my blood drawn for genetic testing for Hypertrophic Cardiomyopathy (HCM). I have really struggled with this decision. The way insurance companies are these days, I worry that something will be used against me in a way I can’t even imagine and I find myself suddenly without coverage. That would be devastating financially.

I am pre-approved by my insurance to have the testing and thanks to a broken lead earlier this year, my deductible has been met so there is no money out of my pocket. Logically, I know everything should be fine, but all those stories of people who thought they were covered being retroactively denied coverage really worry me. I know that the Genetic Information Non-discrimination Act (GINA) has passed and I know its intent to protect people from losing insurance coverage despite any information that genetic testing uncovers. But for ever law there seems to be a loophole and putting my faith in the government and regulations to protect me seems like a lost cause these days.

On the other hand, I understand this is a tricky disease and it seems to me that for all we know, there is a lot that we just don’t know yet. I believe that it is through genetic studies that HCM will come closer to being fully understood. The information I provide with my DNA may not help me directly, but it might help my children to understand their risks and will eventually help doctors solve the some of the mysteries of this heart disease. In the end, this is what motivates me and I agree to get the test. So I today headed back over to Stanford Cardiovascular unit to submit my blood for testing.

This is an easy thing on my part, give a small vile of blood and sit back and wait for the results. My veins are a little shy these days; they have been poked at a lot over the last three months so we decide to use the prominent vein on my hand. It sometimes hurts a little bit more but getting one stick is better then fishing around in my arm for a vein that doesn’t roll out of the way. A quick sign of a release paper and the blood draw and I am on my way. I won’t get any results until sometime after February next year.

I have talked to three others that have had this test and they tell me the same thing, their tests came back as ‘unknown’ meaning they didn’t have any of the known markers for HCM. I am not even going to pretend that I understand all this but if I have my numbers right, there are 17 known genetic mutations for HCM. Of those known mutations, there have been several studies that have shown some correlation with “prognostic significance”. I take that to mean, some genetic mutations that are known for HCM will map to higher likelihood of SCA and other known outcomes. Today I was told there are seventy other markers that may have some contribution. Some of these may not have been associated with HCM but may have been identified with symptoms like arrhythmias or excessive scaring and so on. So even if they don’t find the know causes for HCM, they may gather enough information to prove other markers that were previously unknown or may be able to say that I am more likely to have certain outcomes.

Or they may never get it all figured out, but so far all it cost me was a drive to the Stanford campus and a little blood.

Boston Scientific advisory issued on the COGNIS and TELIGEN families of ICDs.

Boston Scientific has notified the ICD User Group of an important product advisory involving their COGNIS CRT-Ds and TELIGEN ICDs.

This product advisory information is not a recall, and affects only COGNIS and TELIGEN devices implanted below the chest muscles (commonly known as submuscular pectoral, or subpectoral implants). Devices placed subcutaneously (just under the skin) are not affected by this advisory.

About 95% percent of defibrillators are implanted subcutaneously. Less commonly, a doctor may choose to implant a device deeper, under the chest muscles. Boston Scientific has learned that devices implanted under the chest muscles may be subject to mechanical stress that could weaken the bond between the device casing and the lead connector, or header, portion of the device, and could impact the ability to deliver appropriate therapy.

According to Boston Scientific, a weakened header bond can also result in one or more of the following:

• Significant changes in measured lead impedance
• Noise on real-time or stored electrograms
• Intermittent inhibition of pacing
• Inappropriate anti-tachycardia pacing or shock therapy
• Loss of pacing therapy
• Loss of anti-tachycardia pacing and shock therapy

To date, Boston Scientific says it has received only two reports worldwide of implants located under the chest muscles with weakened header bonds. The patients implanted with these devices received inappropriate shocks and were required to have their devices replaced earlier than expected.

Boston Scientific has notified regulatory authorities of this problem and has communicated this issue to physicians. They have also submitted manufacturing process improvements to the FDA and will implement such changes when regulatory approval is received.

Again, only COGNIS and TELIGEN devices implanted below the chest muscles are affected by this advisory. Boston Scientific estimates that this consists of only about 5% of the 77,000 devices implanted worldwide.

WHAT YOU SHOULD DO:

• If you don’t already know what device model you have, check your ID card to determine whether you have a COGNIS or TELIGEN. If you don’t, this advisory does not apply.


• Talk to your doctor to determine whether your device is implanted under the skin, or under the chest muscle. If your device is implanted just under the skin, this advisory does not apply.


• Attend your regular device follow-up appointments


• Immediately contact your device doctor or clinic if you receive a shock

This advisory is publicly available on Boston Scientific’s website, under the Product Performance Resource Center link. A PDF of current Product Advisories can be downloaded here.

In addition to the above, Boston Scientific’s Patient Advocacy & Education and Patient Services teams are available to support you and answer any questions you may have. Patients should contact Boston Scientific Patient Services at 1 (866) 484-3268. Press “2” when prompted.

In an email to the ICD User Group, Boston Scientific explained that it’s taken the initiative to inform us in hopes that the information will get out there in a resposible and accurate manner. They’ve also stated that they recognize the importance of advocacy groups as an “important and credible resource for patients.”

Here’s a link to this Product Advisory on Boston Scientific’s web site.